Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial In Arteriosclerosis, Thrombosis, and Vascular Biology; 2019; Vol 39 Issue 5; 956-964. Published on April 25th, 2019 Authors Christine Voors-Pette, Kristell Lebozec, Peter Dogterom, Laurie Jullien, Philippe Billiald, Pauline Ferlan, Lionel Renaud, Olivier Favre-Bulle, Gilles Avenard, Matthias […]

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development In New Biotechnology, 2018 Authors Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, Olivier Favre-Bulle, and Philippe Billiald. Abstract Monoclonal antibody fragments (Fab) are a promising class of therapeutic agents. Fabs are aglycosylated […]

Design, development and characterization of ACT017, a humanized Fab that blocks platelet’s glycoprotein VI function without causing bleeding risks In mAbs, 2017, VOL. 0, NO. 0, 1–14, published on Jun, 9th 2017 Authors Kristell Lebozec, Martine Jandrot-Perrus, Gilles Avenard, Olivier Favre-Bulle, and Philippe Billiald. Abstract Glycoprotein VI is a platelet-specific collagen receptor critical for in […]

Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke In International Journal of Stroke 0(0) 1–8, published on May, 2016 Authors Isuru Induruwa1, Stephanie M Jung2 and Elizabeth A Warburton1 Abstract Background: Platelets are essential to physiological hemostasis or pathological thrombus formation. Current antiplate- let agents inhibit platelet aggregation but leave patients at risk of systemic […]

Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials In Lancet 2016; 387: 1723–31, published on February 18, 2016 Authors Mayank Goyal, Bijoy K Menon, Wim H van Zwam, Diederik W J Dippel, Peter J Mitchell, Andrew M Demchuk, Antoni Dávalos, Charles B L M Majoie, Aad van der Lugt, […]

Antiplatelet drugs: which targets for which treatments? In Journal of Thrombosis and Haemostasis, 13 (Suppl. 1): S313–S322, 2015 Authors Christian Gachet Abstract The current standard care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous […]